Dysregulation of parkin in the substantia nigra of db/db and high-fat diet mice

Neuroscience

Volumn 294, Issue , 2015, Pages 182-192

  Khang, R ^a   Park, C ^a   Shin, J H ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Metformin; PARIS; Parkin; Parkinson's disease; Type 2 diabetes

Indexed keywords

DJ 1 PROTEIN; MARKER; METFORMIN; MITOCHONDRIAL PROTEIN; PARKIN; PARKIN INTERACTING SUBSTRATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PHOSPHATASE AND TENSIN HOMOLOG INDUCED PUTATIVE KINASE 1; UNCLASSIFIED DRUG; DOPAMINE; REPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE; ZNF746 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DB/DB MOUSE; DIABETES MELLITUS; DOPAMINERGIC NERVE CELL; DOWN REGULATION; IMMUNOBLOTTING; LIPID DIET; LIQUID CHROMATOGRAPHY; MALE; MOUSE; NERVE DEGENERATION; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEOMICS; SUBSTANTIA NIGRA; TANDEM MASS SPECTROMETRY; ANIMAL; ANIMAL FOOD; EXPERIMENTAL DIABETES MELLITUS; GENETICS; KNOCKOUT MOUSE; METABOLISM; MITOCHONDRION;

ANIMAL FEED; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DOPAMINE; DOPAMINERGIC NEURONS; MICE, KNOCKOUT; MITOCHONDRIA; PARKINSON DISEASE; REPRESSOR PROTEINS; SUBSTANTIA NIGRA; UBIQUITIN-PROTEIN LIGASES;

EID: 84925803640     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2015.03.017     Document Type: Article

References (32)

1. Ashabi G., Khodagholi F., Khalaj L., Goudarzvand M., Nasiri M. Activation of AMP-activated protein kinase by metformin protects against global cerebral ischemia in male rats: interference of AMPK/PGC-1α pathway. Metab Brain Dis 2014, 29:47-58.
2. Belgardt B.F., Bruning J.C. CNS leptin and insulin action in the control of energy homeostasis. Ann N Y Acad Sci 2010, 1212:97-113.
3. Bhatia V.N., Perlman D.H., Costello C.E., McComb M.E. Software tool for researching annotations of proteins: open-source protein annotation software with data visualization. Anal Chem 2009, 81:9819-9823.
4. Chen H., Charlat O., Tartaglia L.A., Woolf E.A., Weng X., Ellis S.J., Lakey N.D., Culpepper J., Moore K.J., Breitbart R.E., Duyk G.M., Tepper R.I., Morgenstern J.P. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 1996, 84:491-495.
5. Dawson T.M., Dawson V.L. The role of parkin in familial and sporadic Parkinson's disease. Mov Disord 2010, 25(Suppl. 1):S32-S39.
6. Dawson T.M., Dawson V.L. Parkin plays a role in sporadic Parkinson's disease. Neurodegener Dis 2014, 13:69-71.
7. El-Mir M.Y., Detaille D., Villanueva G.R., Delgado-Esteban M., Guigas B., Attia S., Fontaine E., Almeida A., Leverve X. Neuroprotective role of antidiabetic drug metformin against apoptotic cell death in primary cortical neurons. J Mol Neurosci 2008, 34:77-87.
8. Elmquist J.K., Flier J.S. The fat-brain axis enters a new dimension. Science 2004, 304:63-64.
9. Hu G., Jousilahti P., Bidel S., Antikainen R., Tuomilehto J. Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 2007, 30:842-847.
10. Jensen L.J., Kuhn M., Stark M., Chaffron S., Creever C., Muller J., Doerks T., Julien P., Roth A., Simonovic M., Bork P., von Mering C. STRING 8 - a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res 2009, 37:D412-D416.
11. Khang R., Park C., Shin J.H. The biguanide metformin alters phosphoproteomic profiling in mouse brain. Neurosci Lett 2014, 579:145-150.
12. Kirpichnikov D., McFarlane S.I., Sowers J.R. Metformin: an update. Ann Intern Med 2002, 137:25-33.
13. Kitada T., Asakawa S., Hattori N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998, 392:605-608.
14. Labouesse M.A., Stadlbauer U., Langhans W., Meyer U. Chronic high fat diet consumption impairs sensorimotor gating in mice. Psychoneuroendocrinology 2013, 38:2562-2574.
15. Lee G.H., Proenca R., Montez J.M., Carroll K.M., Darvishzadeh J.G., Lee J.I., Friedman J.M. Abnormal splicing of the leptin receptor in diabetic mice. Nature 1996, 379:632-635.
16. Lees A.J., Hardy J., Revesz T. Parkinson's disease. Lancet 2009, 373:2055-2066.
17. Lu M., Hu G. Targeting metabolic inflammation in Parkinson's disease: implications for prospective therapeutic strategies. Clin Exp Pharmacol Physiol 2012, 39:577-585.
18. Lu F.P., Lin K.P., Kuo H.K. Diabetes and the risk of multi-system aging phenotypes: a systematic review and meta-analysis. PLoS One 2009, 4:e4144.
19. Martin-Montalvo A., Mercken E.M., Mitchell S.J., Palacios H.H., Mote P.L., Scheibye-Knudsen M., Gomes A.P., Ward T.M., Minor R.K., Blouin M.-J., Schwab M., Pollak M., Zhang Y., Yu Y., Becker K.G., Bohr V.A., Ingram D.K., Sinclair D.A., Wolf N.S., Spindler S.R., Bernier M., de Cabo R. Metformin improves healthspan and lifespan in mice. Nat Commun 2013, 4:2192.
20. Mielke J.G., Taghibiglou C., Wang Y.T. Endogenous insulin signaling protects cultured neurons from oxygen-glucose deprivation-induced cell death. Neuroscience 2006, 143:165-173.
21. Parekh P.I., Petro A.E., Tiller J.M., Feinglos M.N., Surwit R.S. Reversal of diet-induced obesity and diabetes in C57BL/6J mice. Metabolism 1998, 47:1089-1096.
22. Patrone C., Eriksson O., Lindholm D. Diabetes drugs and neurological disorders: new views and therapeutic possibilities. Lancet Diabetes Endocrinol 2014, 2:256-262.
23. Pintana H., Apaijai N., Pratchayasakul W., Chattipakorn N., Chattipakorn S.C. Effects of metformin on learning and memory behaviors and brain mitochondrial functions in high fat diet induced insulin resistant rats. Life Sci 2012, 91:409-414.
24. Santiago J.A., Potashkin J.A. Shared dysregulated pathways lead to Parkinson's disease and diabetes. Trends Mol Med 2013, 19:176-186.
25. Savitt J.M., Dawson V.L., Dawson T.M. Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 2006, 116:1744-1754.
26. Schernhammer E., Hansen J., Rugbjerg K., Wermuth L., Ritz B. Diabetes and the risk of developing Parkinson's disease in Denmark. Diabetes Care 2011, 34:1102-1108.
27. Shevchenko A., Tomas H., Havlis J., Olsen J.V., Mann M. In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nat Protoc 2006, 1:2856-2860.
28. Shin J.H., Ko H.S., Kang H., Lee Y., Lee Y.I., Pletinkova O., Troconso J.C., Dawson V.L., Dawson T.M. PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease. Cell 2011, 144:689-702.
29. Ullah I., Ullah N., Naseer M.I., Lee H.Y., Kim M.O. Neuroprotection with metformin and thymoquinone against ethanol-induced apoptotic neurodegeneration in prenatal rat cortical neurons. BMC Neurosci 2012, 13:11.
30. Van Heek M., Compton D.S., France C.F., Tedesco R.P., Fawzi A.B., Graziano M.P., Sybertz E.J., Strader C.D., Davis H.R. Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J Clin Invest 1997, 99:385-390.
31. Wang L., Zhai Y.Q., Xu L.L., Qiao C., Sun X.L., Ding J.H., Lu M., Hu G. Metabolic inflammation exacerbates dopaminergic neuronal degeneration in response to acute MPTP challenge in type 2 diabetes mice. Exp Neurol 2014, 251:22-29.
32. Xu Q., Park Y., Huang X., Hollenbeck A., Blair A., Schatzkin A., Chen H. Diabetes and risk of Parkinson's disease. Diabetes Care 2011, 34:910-915.